Placeholder Banner

BIO Comments on FDA Draft Guidance on Biomarker Qualification: Evidentiary Framework

February 11, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Biomarker Qualification: Evidentiary Framework.

The guidance provides industry and FDA staff with recommendations on considerations to address when developing a biomarker qualification under the 21st Century Cures Act, which added a new section to the Federal Food, Drug and Cosmetic Act.

BIO recognizes FDA’s efforts to clarify the evidentiary standards for biomarker qualification but suggests the guidance should include timelines. BIO commends FDA for including language about the use of biomarkers in an individual drug development program (e.g., investigational new drug application, new drug application, or biologics license application submissions), but asks FDA to make note of areas where there may need to be flexibility, such as in the case of rare diseases where there are limited populations.

The comments also discuss qualification of a biomarker that already has an established, specific context of use (COU), a pilot program to engage external experts to support the review of biomarker qualification submissions, and FDA’s plans to share information about submissions.

Download Full Comments Below
BIO Letter Biomarker Qualification Draft Guidance FDA-2018-D-4267
Read full comment letter below
Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…